Hem/Onc Pharmacology Section 17- Rituximab, Bevacizumab, Alemtuzumab, Cetuximab, Panitumumab, and Trastuzumab

TOPICS: Rituximab, anti cd 20 monoclinic antibody, non hodgkin lymphoma, waldenstrom macroglobulinemia, raynaud's phenomenon, thrombotic thrombocytopenic purpura, rheumatoid arthritis, multiple sclerosis, autoimmune hemolytic anemia, cll, progressive multifocal leukoencephalopathy, bevacizumab, monoclonal antibody, vegf, angiogenesis, colorectal cancer, renal cell carcinoma, non small cell lung cancer, wet macular degeneration, hemorrhage, impaired wound healing, blood clots, alemtuzumab, cd 52, cll, multiple sclerosis, cetuximab, panitumumab, egfr, stage IV colorectal cancer, wild type kras, head and neck cancer, rash, elevated lfts, diarrhea, trastuzumab, her2, her2+ breast cancer, gastric cancer, dilated cardiomyopathy
Go Back

Upgrade Now to Access All Content

Upgrade Now

Please register for a FREE account to get FREE access to all of our Microbiology videos.